Soleo Health Equipped to Fulfill Growing Need for FDA-Approved LEQEMBI™ (lecanemab-irmb) for Alzheimer's Disease Treatment
Soleo Health, a prominent national provider of specialized pharmacy services, is prepared to address the increasing demand for LEQEMBI™ (lecanemab-irmb), an FDA-approved medication for the treatment of Alzheimer's disease.
chandni
Soleo Health, a pioneering leader and nationwide provider of specialized pharmacy services, has announced its readiness to meet the growing demand for the FDA-approved LEQEMBI™ (lecanemab-irmb) medication in the treatment of Alzheimer's disease. Following the drug's full approval by the Food and Drug Administration (FDA), Soleo Health is well-positioned to address the needs of patients prescribed THE GROUP™.
In January 2023, Soleo Health was chosen by Eisai Inc., a pharmaceutical developer, as the specialty pharmacy distribution partner for LEQEMBI, a highly anticipated anti-amyloid monoclonal antibody used to treat early stages of Alzheimer's disease, including mild cognitive impairment and mild Alzheimer's disease. With LEQEMBI now receiving full FDA approval, Soleo Health has expanded its clinical network and operations to accommodate the anticipated surge in demand.
Patients who receive LEQEMBI through Soleo Health can undergo treatment at any of the company's 35+ Ambulatory Infusion Centers (AIC) nationwide or in the comfort of their homes. The specialized care is provided by the Soleo Health Alzheimer's Therapeutic Care Management Center (TCMC), comprising interdisciplinary teams of experienced therapeutic care pharmacists, registered nurses, reimbursement specialists, and patient care ambassadors. Soleo Health's dedicated Alzheimer's disease TCMC is supported by its specialty pharmacy locations across all 50 states.
Drew Walk, the CEO of Soleo Health, expressed the significance of LEQEMBI in advancing Alzheimer's disease treatment and the company's commitment to meeting the growing demand. As a trusted partner, Soleo Health simplifies complex care and enhances medication accessibility for patients, collaborating closely with physicians, patients, and families throughout their LEQEMBI treatment journeys. Soleo Health's expertise in caring for patients with Alzheimer's disease, as well as rare and ultra-rare diseases, played a key role in its selection as the specialist pharmacy provider for LEQEMBI.
In addition to providing treatment at home and AICs, Soleo Health distributes LEQEMBI to prescription offices and infusion centers, further expanding its reach in delivering this vital medication.
